Protara Therapeutics, Inc. (TARA)
| Market Cap | 79.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -45.83M |
| Shares Out | 11.24M |
| EPS (ttm) | -4.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 93,527 |
| Open | 7.02 |
| Previous Close | 7.39 |
| Day's Range | 6.95 - 7.34 |
| 52-Week Range | 6.18 - 27.51 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 37.33 (+427.3%) |
| Earnings Date | Nov 11, 2021 |
About TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price forecast is 37.33, which is an increase of 427.26% from the latest price.
News
Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview
– TARA-002 Confirmatory Large-Scale GMP Comparability Complete –
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today a...
11 Things to Know About Protara Therapeutics as TARA Stock Soars on Big FDA News
Protara Therapeutics (TARA) stock is heading higher on Tuesday following some major news from the FDA concerning clinical trials. The post 11 Things to Know About Protara Therapeutics as TARA Stock Soar...
Why Protara Therapeutics Stock Is Rising Today
Protara Therapeutics Inc (NASDAQ: TARA) is trading higher Tuesday after the company announced FDA clearance of the Investigational New Drug application for TARA-002 for the treatment of non-muscle invas...
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment o...
- Company Plans to Initiate Phase 1 Study of TARA-002 by Year-End -
Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with si...
Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview
- Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End -
New Strong Sell Stocks for June 29th
ITRG, TARA, QTNT, VNCE and APDN have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2021.
Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...
2 Falling Knives to Catch
Unexpectedly, Wall Street recommends acquiring shares of Protara Therapeutics Inc ( TARA , Financial) and IMARA Inc ( IMRA , Financial), despite the fact that these two equities have shown poor performa...
Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview
- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End -
Why Novavax, Inovio, and Protara Are Moving Today
Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Protara Therapeutics, Inc. (NASDAQ: TARA) are among the biotech movers Friday. Novavax Moves On Mid-stage Malaria Vaccine Dat...
Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations
Company to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in Lymphatic Malformations Company to conduct additional clinical study to support subm...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with si...
Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with si...
Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview
- Initiation of Phase 1 Trial of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer on Track to Commence by Year-End -
Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...
3 Net-Net Working Capital Stocks
There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has reassesse...
Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...
Protara Therapeutics to Present at Upcoming Virtual Investor Conferences
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...
Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview
- On T rack to Complete GMP Batch Runs in Mid-2021 to C onfirm C omparability B etween TARA-002 and OK-432 - - Expect to I nitiate Phase 1 T rial for TARA-002 in P atients with N on- M uscle I nvasive B...
Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...
Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock...
NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with ...
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with ...
Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncolo...
- Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs -